Meghmani Organics Q1 FY27: Revenue Down 12% to ₹522.9 Cr, EBITDA Up 16% to ₹93.7 Cr
Meghmani Organics Limited reported Q1 FY27 revenue of ₹522.9 crore (down 12% YoY) and EBITDA of ₹93.7 crore (up 16% YoY). The Crop Protection segment contributed ₹391.6 crore in revenue, while Pigments contributed ₹131.3 crore. The company is also progressing with its scheme of amalgamation to merge KCL and MCNL into MOL.
The results show mixed performance with revenue decline but improved profitability. The ongoing amalgamation is a significant corporate action that could have a medium-term impact on the company's structure and operations.
While EBITDA increased and margins improved, revenue saw a decline due to softer demand, making the overall sentiment neutral.
Meghmani Organics Limited (MOL) has released its investor presentation for the first quarter of FY27, ending June 30, 2026. The company reported revenue from operations at ₹522.9 crore, a 12% decrease year-on-year. However, EBITDA saw a significant increase of 16% year-on-year, reaching ₹93.7 crore, with an improved EBITDA margin of 17.9%.
The Crop Protection segment, which constitutes approximately 75% of the company's revenue, recorded revenue of ₹391.6 crore and EBITDA of ₹77.8 crore, with an EBITDA margin of 19.9%. Production in this segment was 8,880 MT, with a capacity utilization of 63%. The Pigments segment, contributing about 25% of the revenue, reported revenue of ₹131.3 crore and EBITDA of ₹15.9 crore, resulting in an EBITDA margin of 12.1%. Production in the Pigments segment was 3,233 MT, with a capacity utilization of 39%.
The company's financial performance in Q1 FY27 was impacted by softer demand due to macroeconomic uncertainties, but better price realization and a favorable product mix contributed to improved profitability. MOL also provided an update on its ongoing scheme of amalgamation, where Kilburn Chemicals Limited (KCL) and Meghmani Crop Nutrition Limited (MCNL) will be merged with MOL to simplify the group structure into a single listed entity, derive operational and financial synergies, and strengthen its market positioning. The scheme has received board approval and is progressing through NCLT proceedings.
What to do with a filing like this
Meghmani Organics Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Meghmani Organics Limited. Read the original for the full detail.